Compass Therapeutics, Inc. Quarterly Debt-to-equity in % from Q4 2018 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Compass Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q4 2018 to Q2 2025.
  • Compass Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2025 was 15.1 %, a 190% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 15.1 +9.89 +190% Jun 30, 2025
Q1 2025 10.9 +5.63 +107% Mar 31, 2025
Q4 2024 6.97 +0.54 +8.4% Dec 31, 2024
Q3 2024 5.54 -1.99 -26.4% Sep 30, 2024
Q2 2024 5.22 -3.1 -37.3% Jun 30, 2024
Q1 2024 5.25 -4.04 -43.5% Mar 31, 2024
Q4 2023 6.43 -3.43 -34.8% Dec 31, 2023
Q3 2023 7.53 -2.28 -23.2% Sep 30, 2023
Q2 2023 8.32 -3.46 -29.4% Jun 30, 2023
Q1 2023 9.3 -5.6 -37.6% Mar 31, 2023
Q4 2022 9.86 -12.9 -56.6% Dec 31, 2022
Q3 2022 9.81 -29.6 -75.1% Sep 30, 2022
Q2 2022 11.8 -23.1 -66.2% Jun 30, 2022
Q1 2022 14.9 -18 -54.8% Mar 31, 2022
Q4 2021 22.7 -249 -91.6% Dec 31, 2021
Q3 2021 39.4 +424 Sep 30, 2021
Q2 2021 34.8 +56 Jun 30, 2021
Q1 2021 32.9 +38.8 Mar 31, 2021
Q4 2020 271 +278 Dec 31, 2020
Q3 2020 -385 -385 -475975% Sep 30, 2020
Q2 2020 -21.2 -21.1 -21161% Jun 30, 2020
Q1 2020 -5.89 -5.75 -4209% Mar 31, 2020
Q4 2019 -6.45 -6.21 -2569% Dec 31, 2019
Q3 2019 -0.08 Sep 30, 2019
Q2 2019 -0.1 Jun 30, 2019
Q1 2019 -0.14 Mar 31, 2019
Q4 2018 -0.24 Dec 31, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.